Sildenafil preserves lung endothelial function and prevents pulmonary vascular remodeling in a rat model of diastolic heart failure

Circulation: Heart Failure

Volumn 4, Issue 2, 2011, Pages 198-206

  Yin, Jun ^a,b,c   Kukucka, Marian ^b   Hoffmann, Julia ^d   Sterner Kock, Anja ^e   Burhenne, Juergen ^f   Haefeli, Walter E ^f   Kuppe, Hermann ^b   Kuebler, Wolfgang M ^a,b,d,g  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^c AFFILIATED PEOPLE S HOSPITAL OF JIANGSU UNIVERSITY   (China)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY OF COLOGNE   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g UNIVERSITY OF TORONTO   (Canada)

Author keywords

Congestive heart failure; Endothelial dysfunction; Pulmonary hypertension; Vascular remodeling

Indexed keywords

NITRIC OXIDE; SILDENAFIL; ANTIHYPERTENSIVE AGENT; CYCLIC GMP; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SULFONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA OCCLUSION; ARTERIAL WALL THICKNESS; ARTICLE; BIOSYNTHESIS; CONTROLLED STUDY; DIASTOLIC HEART FAILURE; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; EXPERIMENTAL MODEL; HEART PROTECTION; HEART RIGHT VENTRICLE FUNCTION; HEART VENTRICLE HYPERTROPHY; HISTOPATHOLOGY; LONG TERM CARE; LUNG BLOOD VESSEL; LUNG ENDOTHELIUM; LUNG VASCULAR RESISTANCE; MALE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULMONARY VASCULAR REMODELING; RAT; TISSUE STRUCTURE; VASODILATATION; ANIMAL; BLOOD; DISEASE MODEL; DRUG EFFECT; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE HYPERTROPHY; LUNG; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOLOGY; PATHOPHYSIOLOGY; PULMONARY ARTERY; SPRAGUE DAWLEY RAT; TIME; VASCULAR ENDOTHELIUM; VASCULAR RESISTANCE; VASCULARIZATION;

ADMINISTRATION, ORAL; ANIMALS; ANTIHYPERTENSIVE AGENTS; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; HEART FAILURE, DIASTOLIC; HYPERTENSION, PULMONARY; HYPERTROPHY, LEFT VENTRICULAR; HYPERTROPHY, RIGHT VENTRICULAR; LUNG; MALE; NITRIC OXIDE; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PULMONARY ARTERY; PURINES; RATS; RATS, SPRAGUE-DAWLEY; SULFONES; TIME FACTORS; VASCULAR RESISTANCE; VASODILATION; VENTRICULAR FUNCTION, LEFT; VENTRICULAR FUNCTION, RIGHT;

EID: 79955941261     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.110.957050     Document Type: Article

References (50)

1. Ghio S, Gavazzi A, Campana C, Inserra C, Klersy C, Sebastiani R, Arbustini E, Recusani F, Tavazzi L. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol. 2001;37: 183-188. (Pubitemid 32051736)
2. Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM. Pulmonary hypertension in heart failure with preserved ejection fraction: A community-based study. J Am Coll Cardiol. 2009;53: 1119-1126.
3. Huang W, Kingsbury MP, Turner MA, Donnelly JL, Flores NA, Sheridan DJ. Capillary filtration is reduced in lungs adapted to chronic heart failure: Morphological and haemodynamic correlates. CardiovascRes. 2001;49:207-217.
4. Delgado JF, Conde E, Sanchez V, Lopez-Rios F, Gomez-Sanchez MA, Escribano P, Sotelo T, Gomez de la CA, Cortina J, de la Calzada CS. Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure. Eur J Heart Fail. 2005;7:1011-1016. (Pubitemid 41443595)
5. Ben Driss A, Devaux C, Henrion D, Duriez M, Thuillez C, Levy BI, Michel JB. Hemodynamic stresses induce endothelial dysfunction and remodeling of pulmonary artery in experimental compensated heart failure. Circulation. 2000;101:2764-2770. (Pubitemid 30390582)
6. Wood P, Besterman EM, Towers MK, McIlroy MB. The effect of acetylcholine on pulmonary vascular resistance and left atrial pressure in mitral stenosis. Br Heart J. 1957;19:279-286.
7. Moraes DL, Colucci WS, Givertz MM. Secondary pulmonary hypertension in chronic heart failure: The role of the endothelium in pathophysiology and management. Circulation. 2000;102:1718-1723.
8. Archer SL, Michelakis ED. Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. N Engl J Med. 2009;361:1864-1871.
9. Lewis GD, Lachmann J, Camuso J, Lepore JJ, Shin J, Martinovic ME, Systrom DM, Bloch KD, Semigran MJ. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation. 2007;115:59-66. (Pubitemid 46058612)
10. Guazzi M, Tumminello G, Di MF, Fiorentini C, Guazzi MD. The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. J Am Coll Cardiol. 2004;44:2339-2348. (Pubitemid 39647608)
11. Guazzi M, Samaja M, Arena R, Vicenzi M, Guazzi MD. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol. 2007;50:2136-2144. (Pubitemid 350117342)
12. Lewis GD, Shah R, Shahzad K, Camuso JM, Pappagianopoulos PP, Hung J, Tawakol A, Gerszten RE, Systrom DM, Bloch KD, Semigran MJ. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation. 2007;116:1555-1562. (Pubitemid 47511419)
13. Yin N, Kaestle S, Yin J, Hentschel T, Pries AR, Kuppe H, Kuebler WM. Inhaled nitric oxide versus aerosolized iloprost for the treatment of pulmonary hypertension with left heart disease. Crit Care Med. 2009;37: 980-986.
14. Hentschel T, Yin N, Riad A, Habbazettl H, Weimann J, Koster A, Tschope C, Kuppe H, Kuebler WM. Inhalation of the phosphodiesterase-3 inhibitor milrinone attenuates pulmonary hypertension in a rat model of congestive heart failure. Anesthesiology. 2007;106:124-131. (Pubitemid 46035412)
15. Sasser JM, Baylis C. Effects of sildenafil on maternal hemodynamics and fetal growth in normal rat pregnancy. Am J Physiol Regul Integr Comp Physiol. 2010;298:R433-R438.
16. Linehan JH, Haworth ST, Nelin LD, Krenz GS, Dawson CA. A simple distensible vessel model for interpreting pulmonary vascular pressure-flow curves. J Appl Physiol. 1992;73:987-994.
17. Nyengaard JR, Bendtsen TF, Bjugn R, Lokkegaard A, Tang Y, Gundersen HJG. A stereological approach to capillary networks. In: Sharma AK, ed. Morphometry: Applications to Medical Sciences. New Dehli, India: Macmillan India Ltd; 1996:217-231.
18. Yin J, Hoffmann J, Kaestle SM, Neye N, Wang L, Baeurle J, Liedtke W, Wu S, Kuppe H, Pries AR, Kuebler WM. Negative-feedback loop attenuates hydrostatic lung edema via a cGMP-dependent regulation of transient receptor potential vanilloid 4. Circ Res. 2008;102:966-974. (Pubitemid 351591552)
19. Adnot S, Raffestin B, Eddahibi S, Braquet P, Chabrier PE. Loss of endothelium-dependent relaxant activity in the pulmonary circulation of rats exposed to chronic hypoxia. J Clin Invest. 1991;87:155-162.
20. Rich S, Rabinovitch M. Diagnosis and treatment of secondary (noncategory 1) pulmonary hypertension. Circulation. 2008;118:2190-2199.
21. Barst RJ, Gibbs JS, Ghofrani HA, Hoeper MM, McLaughlin VV, Rubin LJ, Sitbon O, Tapson VF, Galie N. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2009; 54:S78-S84.
22. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, Bedja D, Gabrielson KL, Wang Y, Kass DA. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med. 2005;11:214-222. (Pubitemid 40321358)
23. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: Appreciating the scope of the heart failure epidemic. JAMA. 2003;289:194-202. (Pubitemid 36068707)
24. Nagayama T, Hsu S, Zhang M, Koitabashi N, Bedja D, Gabrielson KL, Takimoto E, Kass DA. Pressure-overload magnitude-dependence of the anti-hypertrophic efficacy of PDE5A inhibition. J Mol Cell Cardiol. 2009;46:560-567.
25. Takimoto E, Koitabashi N, Hsu S, Ketner EA, Zhang M, Nagayama T, Bedja D, Gabrielson KL, Blanton R, Siderovski DP, Mendelsohn ME, Kass DA. Regulator of g protein signaling 2 mediates cardiac compen sation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice. J Clin Invest. 2009;119:408-420.
26. Li B, Yang L, Shen J, Wang C, Jiang Z. The antiproliferative effect of sildenafil on pulmonary artery smooth muscle cells is mediated via upregulation of mitogen-activated protein kinase phosphatase-1 and degradation of extracellular signal-regulated kinase 1/2 phosphorylation. Anesth Analg. 2007;105:1034-1041. (Pubitemid 47479318)
27. Hemnes AR, Zaiman A, Champion HC. PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and rhoa/rho kinase activation. Am J Physiol Lung Cell Mol Physiol. 2008;294:L24-L33. (Pubitemid 351380315)
28. Wharton J, Strange JW, Moller GM, Growcott EJ, Ren X, Franklyn AP, Phillips SC, Wilkins MR. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med. 2005;172:105-113. (Pubitemid 40923321)
29. Nagendran J, Archer SL, Soliman D, Gurtu V, Moudgil R, Haromy A, St Aubin C, Webster L, Rebeyka IM, Ross DB, Light PE, Dyck JR, Michelakis ED. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation. 2007;116:238-248. (Pubitemid 47196559)
30. Chen Y, Traverse JH, Hou M, Li Y, Du R, Bache RJ. Effect of PDE5 inhibition on coronary hemodynamics in pacing-induced heart failure. Am J Physiol Heart Circ Physiol. 2003;284:H1513-H1520. (Pubitemid 36460761)
31. Schermuly RT, Pullamsetti SS, Kwapiszewska G, Dumitrascu R, Tian X, Weissmann N, Ghofrani HA, Kaulen C, Dunkern T, Schudt C, Voswinckel R, Zhou J, Samidurai A, Klepetko W, Paddenberg R, Kummer W, Seeger W, Grimminger F. Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: Target for reverse-remodeling therapy. Circulation. 2007;115:2331-2339. (Pubitemid 46685901)
32. Pauvert O, Lugnier C, Keravis T, Marthan R, Rousseau E, Savineau JP. Effect of sildenafil on cyclic nucleotide phosphodiesterase activity, vascular tone and calcium signaling in rat pulmonary artery. Br J Pharmacol. 2003;139:513-522. (Pubitemid 36819621)
33. Ghofrani HA, Osterloh IH, Grimminger F. Sildenafil: From angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov. 2006;5:689-702. (Pubitemid 44151606)
34. Walker DK, Ackland MJ, James GC, Muirhead GJ, Rance DJ, Wastall P, Wright PA. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica. 1999;29:297-310. (Pubitemid 29140098)
35. Bogdan M, Humbert M, Francoual J, Claise C, Duroux P, Simonneau G, Lindenbaum A. Urinary cGMP concentrations in severe primary pulmonary hypertension. Thorax. 1998;53:1059-1062. (Pubitemid 28567008)
36. Kodama K, Adachi H. Improvement of mortality by long-term E4010 treatment in monocrotaline-induced pulmonary hypertensive rats. J Pharmacol Exp Ther. 1999;290:748-752. (Pubitemid 29344571)
37. Mair J, Jakob G, Dienstl F, Puschendorf B. Cyclic guanosine monophosphate in heart failure. Lancet. 2003;341:1595-1595.
38. Tsutamoto T, Kanamori T, Wada A, Kinoshita M. Uncoupling of atria1 natriuretic peptide extraction and cyclic guanosine monophosphate production in the pulmonary circulation in patients with severe heart failure. J Am Coll Cardiol. 1992;20:541-546.
39. Melenovsky V, Al-Hiti H, Kazdova L, Jabor A, Syrovatka P, Malek I, Kettner J, Kautzner J. Transpulmonary b-type natriuretic peptide uptake and cyclic guanosine monophosphate release in heart failure and pulmonary hypertension: The effects of sildenafil. J Am Coll Cardiol. 2009;54: 595-600.
40. Kerem A, Yin J, Kaestle SM, Hoffmann J, Schoene AM, Singh B, Kuppe H, Borst MM, Kuebler WM. Lung endothelial dysfunction in congestive heart failure: Role of impaired Ca2+ signaling and cytoskeletal reorganization. Circ Res. 2010;106:1103-1116.
41. Kaestle SM, Reich CA, Yin N, Habazettl H, Weimann J, Kuebler WM. Nitric oxide-dependent inhibition of alveolar fluid clearance in hydrostatic lung edema. Am J Physiol Lung Cell Mol Physiol. 2007;293: L859-L869. (Pubitemid 47572234)
42. Katz SD, Balidemaj K, Homma S, Wu H, Wang J, Maybaum S. Acute type 5 phosphodiesterase inhibition with sildenafil enhances flowmediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol. 2000;36:845-851.
43. Salloum FN, Abbate A, Das A, Houser JE, Mudrick CA, Qureshi IZ, Hoke NN, Roy SK, Brown WR, Prabhakar S, Kukreja RC. Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. Am J Physiol Heart Circ Physiol. 2008;294: H1398-H1406. (Pubitemid 351468739)
44. Musicki B, Champion HC, Becker RE, Liu T, Kramer MF, Burnett AL. Erection capability is potentiated by long-term sildenafil treatment: Role of blood flow-induced endothelial nitric-oxide synthase phosphorylation. Mol Pharmacol. 2005;68:226-232. (Pubitemid 41002962)
45. + channels. J Cardiovasc Pharmacol. 2006;47:365-370. (Pubitemid 44309688)
46. Muzaffar S, Shukla N, Srivastava A, Angelini GD, Jeremy JY. Sildenafil citrate and sildenafil nitrate (NCX 911) are potent inhibitors of superoxide formation and gp91phox expression in porcine pulmonary artery endothelial cells. Br J Pharmacol. 2005;146:109-117. (Pubitemid 43086100)
47. Benz PM, Blume C, Seifert S, Wilhelm S, Waschke J, Schuh K, Gertler F, Münzel T, Renné T. Differential VASP phosphorylation controls remodeling of the actin cytoskeleton. J Cell Sci. 2009;122:3954-3965.
48. Kuebler WM. Effects of pressure and flow on the pulmonary endothelium. In: Voelkel N, Rounds S, eds. The Pulmonary Endothelium. Hoboken, NJ: John Wiley & Sons Inc; 2009:309-336.
49. Olschewski H, Olschewski A, Rose F, Schermuly R, Schutte H, Weissmann N, Seeger W, Grimminger F. Physiologic basis for the treatment of pulmonary hypertension. J Lab Clin Med. 2001;138: 287-297. (Pubitemid 33066151)
50. van Veldhuisen DJ, Poole-Wilson PA. The underreporting of results and possible mechanisms of 'negative' drug trials in patients with chronic heart failure. Int J Cardiol. 2001;80:19-27. (Pubitemid 32800800)